Nimotuzumab has been approved to be used in combination with radiotherapy for the treatment of EGFR positive stage III/IV nasopharyngeal carcinoma and has the effect of sensitized radiotherapy12. Here, EGFR is linked to nasopharyngeal carcinoma.